Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 17 of 17 entries
Sorted by: Best Match Show Resources per page
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA.

ACS pharmacology & translational science

Papke B, Azam SH, Feng AY, Gutierrez-Ford C, Huggins H, Pallan PS, Van Swearingen AED, Egli M, Cox AD, Der CJ, Pecot CV.
PMID: 33860195
ACS Pharmacol Transl Sci. 2021 Feb 04;4(2):703-712. doi: 10.1021/acsptsci.0c00165. eCollection 2021 Apr 09.

Oncogenic mutations in the

Cite
Papke B, Azam SH, Feng AY, et al. Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacol Transl Sci. 2021;4(2):703-712doi: 10.1021/acsptsci.0c00165.
Papke, B., Azam, S. H., Feng, A. Y., Gutierrez-Ford, C., Huggins, H., Pallan, P. S., Van Swearingen, A. E. D., Egli, M., Cox, A. D., Der, C. J., & Pecot, C. V. (2021). Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS pharmacology & translational science, 4(2), 703-712. https://doi.org/10.1021/acsptsci.0c00165
Papke, Bjoern, et al. "Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA." ACS pharmacology & translational science vol. 4,2 (2021): 703-712. doi: https://doi.org/10.1021/acsptsci.0c00165
Papke B, Azam SH, Feng AY, Gutierrez-Ford C, Huggins H, Pallan PS, Van Swearingen AED, Egli M, Cox AD, Der CJ, Pecot CV. Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacol Transl Sci. 2021 Feb 04;4(2):703-712. doi: 10.1021/acsptsci.0c00165. eCollection 2021 Apr 09. PMID: 33860195; PMCID: PMC8033609.
Copy Download .nbib Format: NLM
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.

Cell reports

Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ.
PMID: 34192548
Cell Rep. 2021 Jun 29;35(13):109291. doi: 10.1016/j.celrep.2021.109291.

To identify therapeutic targets for KRAS mutant pancreatic cancer, we conduct a druggable genome small interfering RNA (siRNA) screen and determine that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative analysis of genome-scale CRISPR-Cas9 screens also...

Cite
Waters AM, Khatib TO, Papke B, et al. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2021;35(13):109291doi: 10.1016/j.celrep.2021.109291.
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R., Edwards, A. C., Walsh, K. H., Sulahian, R., McFarland, J. M., Kapner, K. S., Gilbert, T. S. K., Stalnecker, C. A., Javaid, S., Barkovskaya, A., Grover, K. R., Hibshman, P. S., Blake, D. R., Schaefer, A., Nowak, K. M., Klomp, J. E., Hayes, T. K., Kassner, M., Tang, N., Tanaseichuk, O., Chen, K., Zhou, Y., Kalkat, M., Herring, L. E., Graves, L. M., Penn, L. Z., Yin, H. H., Aguirre, A. J., Hahn, W. C., Cox, A. D., & Der, C. J. (2021). Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell reports, 35(13), 109291. https://doi.org/10.1016/j.celrep.2021.109291
Waters, Andrew M, et al. "Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition." Cell reports vol. 35,13 (2021): 109291. doi: https://doi.org/10.1016/j.celrep.2021.109291
Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2021 Jun 29;35(13):109291. doi: 10.1016/j.celrep.2021.109291. PMID: 34192548; PMCID: PMC8340308.
Copy Download .nbib Format: NLM
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction.

Biochemical Society transactions

Klomp JE, Klomp JA, Der CJ.
PMID: 33544118
Biochem Soc Trans. 2021 Feb 26;49(1):253-267. doi: 10.1042/BST20200507.

The RAF-MEK-ERK mitogen-activated protein kinase (MAPK) cascade is aberrantly activated in a diverse set of human cancers and the RASopathy group of genetic developmental disorders. This protein kinase cascade is one of the most intensely studied cellular signaling networks...

Cite
Klomp JE, Klomp JA, Der CJ. The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochem Soc Trans. 2021;49(1):253-267doi: 10.1042/BST20200507.
Klomp, J. E., Klomp, J. A., & Der, C. J. (2021). The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochemical Society transactions, 49(1), 253-267. https://doi.org/10.1042/BST20200507
Klomp, Jennifer E, et al. "The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction." Biochemical Society transactions vol. 49,1 (2021): 253-267. doi: https://doi.org/10.1042/BST20200507
Klomp JE, Klomp JA, Der CJ. The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction. Biochem Soc Trans. 2021 Feb 26;49(1):253-267. doi: 10.1042/BST20200507. PMID: 33544118.
Copy Download .nbib Format: NLM
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.

Cell reports

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ.
PMID: 34852220
Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060.

We apply genetic screens to delineate modulators of KRAS mutant pancreatic ductal adenocarcinoma (PDAC) sensitivity to ERK inhibitor treatment, and we identify components of the ATR-CHK1 DNA damage repair (DDR) pathway. Pharmacologic inhibition of CHK1 alone causes apoptotic growth...

Cite
Klomp JE, Lee YS, Goodwin CM, et al. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021;37(9):110060doi: 10.1016/j.celrep.2021.110060.
Klomp, J. E., Lee, Y. S., Goodwin, C. M., Papke, B., Klomp, J. A., Waters, A. M., Stalnecker, C. A., DeLiberty, J. M., Drizyte-Miller, K., Yang, R., Diehl, J. N., Yin, H. H., Pierobon, M., Baldelli, E., Ryan, M. B., Li, S., Peterson, J., Smith, A. R., Neal, J. T., McCormick, A. K., Kuo, C. J., Counter, C. M., Petricoin, E. F., Cox, A. D., Bryant, K. L., & Der, C. J. (2021). CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37(9), 110060. https://doi.org/10.1016/j.celrep.2021.110060
Klomp, Jennifer E, et al. "CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment." Cell reports vol. 37,9 (2021): 110060. doi: https://doi.org/10.1016/j.celrep.2021.110060
Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. PMID: 34852220; PMCID: PMC8665414.
Copy Download .nbib Format: NLM
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.

Cell reports

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ.
PMID: 34852220
Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060.

We apply genetic screens to delineate modulators of KRAS mutant pancreatic ductal adenocarcinoma (PDAC) sensitivity to ERK inhibitor treatment, and we identify components of the ATR-CHK1 DNA damage repair (DDR) pathway. Pharmacologic inhibition of CHK1 alone causes apoptotic growth...

Cite
Klomp JE, Lee YS, Goodwin CM, et al. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021;37(9):110060doi: 10.1016/j.celrep.2021.110060.
Klomp, J. E., Lee, Y. S., Goodwin, C. M., Papke, B., Klomp, J. A., Waters, A. M., Stalnecker, C. A., DeLiberty, J. M., Drizyte-Miller, K., Yang, R., Diehl, J. N., Yin, H. H., Pierobon, M., Baldelli, E., Ryan, M. B., Li, S., Peterson, J., Smith, A. R., Neal, J. T., McCormick, A. K., Kuo, C. J., Counter, C. M., Petricoin, E. F., Cox, A. D., Bryant, K. L., & Der, C. J. (2021). CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell reports, 37(9), 110060. https://doi.org/10.1016/j.celrep.2021.110060
Klomp, Jennifer E, et al. "CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment." Cell reports vol. 37,9 (2021): 110060. doi: https://doi.org/10.1016/j.celrep.2021.110060
Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF, Cox AD, Bryant KL, Der CJ. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060. PMID: 34852220; PMCID: PMC8665414.
Copy Download .nbib Format: NLM
Showing 13 to 17 of 17 entries